138 related articles for article (PubMed ID: 38493004)
1. CFTR function is impaired in a subset of patients with pancreatitis carrying rare CFTR variants.
Angyal D; Kleinfelder K; Ciciriello F; Groeneweg TA; De Marchi G; de Pretis N; Bernardoni L; Rodella L; Tomba F; De Angelis P; Surace C; Pintani E; Alghisi F; de Jonge HR; Melotti P; Sorio C; Lucidi V; Bijvelds MJC; Frulloni L
Pancreatology; 2024 May; 24(3):394-403. PubMed ID: 38493004
[TBL] [Abstract][Full Text] [Related]
2. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis.
LaRusch J; Jung J; General IJ; Lewis MD; Park HW; Brand RE; Gelrud A; Anderson MA; Banks PA; Conwell D; Lawrence C; Romagnuolo J; Baillie J; Alkaade S; Cote G; Gardner TB; Amann ST; Slivka A; Sandhu B; Aloe A; Kienholz ML; Yadav D; Barmada MM; Bahar I; Lee MG; Whitcomb DC;
PLoS Genet; 2014 Jul; 10(7):e1004376. PubMed ID: 25033378
[TBL] [Abstract][Full Text] [Related]
4. Bicarbonate Transport in Cystic Fibrosis and Pancreatitis.
Angyal D; Bijvelds MJC; Bruno MJ; Peppelenbosch MP; de Jonge HR
Cells; 2021 Dec; 11(1):. PubMed ID: 35011616
[TBL] [Abstract][Full Text] [Related]
5. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
6. Personalized CFTR Modulator Therapy for
Graeber SY; Balázs A; Ziegahn N; Rubil T; Vitzthum C; Piehler L; Drescher M; Seidel K; Rohrbach A; Röhmel J; Thee S; Duerr J; Mall MA; Stahl M
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569738
[TBL] [Abstract][Full Text] [Related]
7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
8. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
10. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E; Burgel PR; Hatton A; Bouazza N; Chevalier B; Macey J; Leroy S; Durieu I; Weiss L; Grenet D; Stremler N; Ohlmann C; Reix P; Porzio M; Roux Claude P; Rémus N; Douvry B; Montcouquiol S; Cosson L; Mankikian J; Languepin J; Houdouin V; Le Clainche L; Guillaumot A; Pouradier D; Tissot A; Priou P; Mély L; Chedevergne F; Lebourgeois M; Lebihan J; Martin C; Zavala F; Da Silva J; Lemonnier L; Kelly-Aubert M; Golec A; Foucaud P; Marguet C; Edelman A; Hinzpeter A; de Carli P; Girodon E; Sermet-Gaudelus I; Pranke I;
Eur Respir J; 2023 Oct; 62(4):. PubMed ID: 37696564
[TBL] [Abstract][Full Text] [Related]
11. CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M;D1270N]/dele22_24.
Kleinfelder K; Somenza E; Farinazzo A; Conti J; Lotti V; Latorre RV; Rodella L; Massella A; Tomba F; Bertini M; Sorio C; Melotti P
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982273
[TBL] [Abstract][Full Text] [Related]
12. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.
Johns JD; Rowe SM
BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159
[TBL] [Abstract][Full Text] [Related]
13. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
14. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
[TBL] [Abstract][Full Text] [Related]
15. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
Abou Alaiwa MH; Launspach JL; Grogan B; Carter S; Zabner J; Stoltz DA; Singh PK; McKone EF; Welsh MJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089726
[TBL] [Abstract][Full Text] [Related]
16. Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis.
Schneider A; Larusch J; Sun X; Aloe A; Lamb J; Hawes R; Cotton P; Brand RE; Anderson MA; Money ME; Banks PA; Lewis MD; Baillie J; Sherman S; Disario J; Burton FR; Gardner TB; Amann ST; Gelrud A; George R; Rockacy MJ; Kassabian S; Martinson J; Slivka A; Yadav D; Oruc N; Barmada MM; Frizzell R; Whitcomb DC
Gastroenterology; 2011 Jan; 140(1):162-71. PubMed ID: 20977904
[TBL] [Abstract][Full Text] [Related]
17. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis.
Berg P; Sorensen MV; Rousing AQ; Vebert Olesen H; Jensen-Fangel S; Jeppesen M; Leipziger J
Ann Intern Med; 2022 Nov; 175(11):1543-1551. PubMed ID: 36315944
[TBL] [Abstract][Full Text] [Related]
18. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study.
Bagheri-Hanson A; Nedwed S; Rueckes-Nilges C; Naehrlich L
BMC Pulm Med; 2014 Oct; 14():156. PubMed ID: 25280757
[TBL] [Abstract][Full Text] [Related]
19. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
